Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member
November 18, 2019 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional...
Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results
November 05, 2019 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and nine months ended September 30, 2019. Recent...
Conatus Pharmaceuticals Reports Second Quarter 2019 Financial Results and Program Updates
August 06, 2019 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and six months ended June 30, 2019, and provided updates on...
Conatus to Explore Strategic Alternatives and Implement Restructuring Plan
June 24, 2019 16:06 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, June 24, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that the company has engaged Oppenheimer & Co., Inc., as its financial advisor to assist...
Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis
June 24, 2019 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, June 24, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that top-line results from the company’s ENCORE-LF clinical trial of emricasan did not meet...
Conatus Pharmaceuticals Reports First Quarter 2019 Financial Results and Program Updates
May 02, 2019 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the first quarter ended March 31, 2019, and provided updates on its...
Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis
April 30, 2019 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, April 30, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced a new publication1 in Hepatology Communications detailing results following seven-day...
Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
April 15, 2019 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that the company’s late-breaker oral presentation at The International Liver Congress™ 2019,...
Conatus Pharmaceuticals to Participate in H.C. Wainwright Global Life Sciences Conference
April 02, 2019 07:30 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, April 02, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted an invitation to participate in the H.C. Wainwright Global Life Sciences Conference (April 7-9...
Conatus Announces Top-line Results from ENCORE-NF Phase 2b Clinical Trial in NASH Fibrosis
March 21, 2019 16:05 ET
|
Conatus Pharmaceuticals Inc.
SAN DIEGO, March 21, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced top-line results from the company’s Phase 2b ENCORE-NF clinical trial in patients with...